Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Lixte Biotechnology Holdings, Inc. (OTC: LIXT).

Full DD Report for LIXT

You must become a subscriber to view this report.


Recent News from (OTC: LIXT)

LB-100 and LB-102, Lixte Biotechnology's Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
EAST SETAUKET, NY, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) noted that investigators at the Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada, reported on February 7, 2018 (Lai et al ., Sci. Transl. Med. 1...
Source: GlobeNewswire
Date: February, 09 2018 09:45
Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
EAST SETAUKET, NY--(Marketwired - Apr 17, 2017) - Lixte Biotechnology Holdings, Inc . ( OTCQB : LIXT ) presented a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when comb...
Source: Marketwired
Date: April, 17 2017 09:45
Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
EAST SETAUKET, NY--(Marketwired - Mar 9, 2017) - Lixte Biotechnology Holdings, Inc. ( OTCQB : LIXT ) announced that a late-breaking abstract entitled "Protein phosphatase 2A inhibition with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when co...
Source: Marketwired
Date: March, 09 2017 10:30
First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
EAST SETAUKET, NY--(Marketwired - Jan 4, 2017) - Lixte Biotechnology Holdings, Inc. ( OTCQB : LIXT ) announced the publication online of Phase 1 results of its novel anti-cancer compound in Clinical Cancer Research , entitled "Safety, tolerability, and preliminary activity of LB-100, an ...
Source: Marketwired
Date: January, 04 2017 11:45
Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors
EAST SETAUKET, NY--(Marketwired - Jun 7, 2016) - Lixte Biotechnology Holdings, Inc. ( OTCQB : LIXT ) announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, Director of the Hematol...
Source: Marketwired
Date: June, 07 2016 09:35
Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
EAST SETAUKET, NY--(Marketwired - Feb 3, 2016) -  Lixte Biotechnology Holdings, Inc. ( OTCQB : LIXT ) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a pote...
Source: Marketwired
Date: February, 03 2016 10:00
Lixte Completes Private Placement of Convertible Preferred Stock
EAST SETAUKET, NY--(Marketwired - Jan 25, 2016) - Lixte Biotechnology Holdings, Inc. ( OTCQB : LIXT ) announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common shares at a per share p...
Source: Marketwired
Date: January, 25 2016 10:30
Week In Review: China Pharma Starts New Year With Record Deals
Deals and Financings Jiangsu Hansoh Pharma is planning to raise over $3 billion in an IPO on the Hong Kong market, which would be record amount for a pharma IPO in Hong Kong. One month ago, it was reported that Hansoh would seek $1.5 billion in an initial offering, implying that the report...
Source: SeekingAlpha
Date: January, 10 2016 15:05
Premarket Biotech Digest: My Response, Gilead In 2016, Blow For Vivus
(Announcing December Discounts. Only for the month of December, the first 100 new subscribers will get a huge discount to my popular biotech service. Click this link to find out how much you can save). (Check my other profile for my real-time biotech trade alerts services f...
Source: SeekingAlpha
Date: December, 31 2015 10:11
Lixte Bio license deal in Asia for lead cancer compound for liver cancer
Lixte Biotechnology Holdings ( OTCQB:LIXT ) grants an exclusive license to its lead anti-cancer compound, LB-100, in Asia to Taipei Medical University (TMU), which will determine the effectiveness of LB-100 against hepatocellular carcinoma in clinical trials. More news on: Lixte Biotechn...
Source: SeekingAlpha
Date: December, 30 2015 10:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.500.480.500.4612,800
2018-08-160.4250.4250.450.4252,100
2018-08-150.400.4250.4450.404,000
2018-08-140.340.39650.39650.3313,710
2018-08-130.320.350.350.3231,900

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-176,70012,80052.3438Short
2018-08-1624,90027,50090.5455Short
2018-08-152,0004,00050.0000Short
2018-08-141,70013,71012.3997Cover
2018-08-132,50031,9007.8370Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LIXT.


About Lixte Biotechnology Holdings, Inc. (OTC: LIXT)

Logo for Lixte Biotechnology Holdings, Inc. (OTC: LIXT)

Lixte Biotechnology Holdings, Inc. is a clinical stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.

 

Contact Information

 

 

Current Management

  • John S. Kovach, MD / CEO, Principal Acct. Officer, Principal Fin. Officer
    • John S. Kovach. M.D. founded Lixte and has been its sole administrative officer. Dr. Kovach has directed leading National Cancer Institute designated Comprehensive Cancer Centers at Mayo Clinic, Rochester, Minnesota and City of Hope National Medical Center, Los Angeles, California. He has extensive experience in medical oncology, anticancer drug pharmacology, and in applied medical research, particularly, the early evaluation of new anticancer drugs and the development and management of multidisciplinary highly productive cancer research teams. Dr. Kovach, in consultation with Lixte s advisors and board, is responsible for the selection and prioritization of the scientific directions and goals of Lixte.
  • Eric J Forman / Business Development
  • John S. Kovach, MD /
    • John S. Kovach. M.D. founded Lixte and has been its sole administrative officer. Dr. Kovach has directed leading National Cancer Institute designated Comprehensive Cancer Centers at Mayo Clinic, Rochester, Minnesota and City of Hope National Medical Center, Los Angeles, California. He has extensive experience in medical oncology, anticancer drug pharmacology, and in applied medical research, particularly, the early evaluation of new anticancer drugs and the development and management of multidisciplinary highly productive cancer research teams. Dr. Kovach, in consultation with Lixte s advisors and board, is responsible for the selection and prioritization of the scientific directions and goals of Lixte.

Current Share Structure

  • Market Cap: $7,543,356 - 03/09/2018
  • Authorized: 100,000,000 - 03/08/2018
  • Issue and Outstanding: 58,025,814 - 03/08/2018

 


Recent Filings from (OTC: LIXT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 23 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 09 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 04 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2017
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 26 2017
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 13 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: April, 06 2017
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2017

 

 


Daily Technical Chart for (OTC: LIXT)

Daily Technical Chart for (OTC: LIXT)


Stay tuned for daily updates and more on (OTC: LIXT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: LIXT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LIXT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of LIXT and does not buy, sell, or trade any shares of LIXT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/